Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed strong financial performance, with significant revenue and EBITDA growth, particularly in the U.S. market. The successful integration of ResMetrix and promising opportunities in the Middle East and North Sea further enhance prospects. Despite some concerns about Canadian rig counts, the company plans to defend margins and grow market share. Shareholder returns are supported by a positive net cash position. The Q&A session provided additional confidence in strategic execution and market expansion, justifying a positive outlook for stock price movement.
Third-quarter revenue $46.5 million, a 6% year-over-year improvement. Reasons for change include contributions from ResMetrix acquisition and increased fracturing system sales domestically and in the North Sea.
U.S. revenue Increased by 26% sequentially and 54% year-over-year. Excluding ResMetrix, U.S. revenue improved by 37% year-over-year due to robust contributions from fracturing services, fracturing systems, and tracer diagnostics product lines.
Revenue for the first 9 months of 2025 $133 million, a 13% or over $15 million increase year-over-year. Reasons include higher revenue from U.S., Canada, and international markets.
Adjusted EBITDA for the first 9 months of 2025 $17.5 million, an increase of $3.4 million or 24% year-over-year. Reasons include strategic plan execution and organic growth initiatives.
Free cash flow for the first 9 months of 2025 $6.8 million, an improvement of $6.5 million year-over-year. Reasons include better working capital management and contributions from ResMetrix.
Canadian revenue for the first 9 months of 2025 Increased by 9% year-over-year despite a 6% decline in the average rig count, indicating value addition to customers.
Adjusted gross profit for the third quarter $19.4 million, with an adjusted gross margin of 42%, consistent with the prior year.
Selling, general, and administrative costs for the third quarter $14.8 million, up $700,000 year-over-year due to increased expenses associated with cash-settled stock awards.
Net income for the third quarter $3.8 million or diluted earnings per share of $1.37, compared to $4.1 million or diluted earnings per share of $1.60 in the prior year. Reasons include increased expenses related to stock awards.
Adjusted EBITDA for the third quarter $7 million, exceeding the midpoint of guidance range, including contributions from ResMetrix.
Cash on hand as of September 30, 2025 $25.3 million, with total debt of $7.4 million, resulting in a positive net cash position.
ResMetrix Integration: Progress in integrating ResMetrix, acquired in late July 2025, into NCS operations. Early successes include operational coordination, cost savings, and improved service offerings.
New Product Development: Showcasing Luminate multi-day composite sampling units in Q4 2025 to improve tracer diagnostics. Manufacturing ATRS AICV sliding sleeves and proprietary packers for a 3-well installation to optimize production in mature wells.
Revenue Growth: Revenue increased by 13% year-over-year for the first 9 months of 2025, with growth in U.S., Canada, and international markets. U.S. revenue grew 54% year-over-year in Q3 2025.
International Expansion: Continued success in the North Sea and agreements to grow business in the Middle East. Supporting customer projects in 8 countries globally.
Operational Efficiencies: Generated $6.8 million in free cash flow in the first 9 months of 2025, an improvement of $6.5 million year-over-year. Identified cost savings through ResMetrix integration, including insurance and fleet management.
Financial Performance: Adjusted EBITDA of $17.5 million for the first 9 months of 2025, a 24% increase year-over-year. Cash balance exceeded $25 million as of September 30, 2025.
Core Strategies: Focus on building market positions, capitalizing on high-margin growth opportunities, and commercializing innovative solutions. Examples include expanding tracer diagnostics and fracturing systems into new markets and regions.
Legal Update: Canadian Federal Court of Appeal overturned a prior judgment against NCS, remanding the case for reconsideration and reducing cost reimbursements.
Market and Industry Conditions: Challenging market conditions include a stagnating U.S. rig count, double-digit year-over-year activity declines in Canada, and delays in unconventional jobs in Saudi Arabia. These factors could adversely impact revenue and operational performance.
Oil Market Oversupply: Potential oversupply in the oil market due to increased OPEC+ oil supply poses risks to pricing and demand, which could negatively affect the company's financial performance.
Tariffs and Trade Uncertainties: Ongoing uncertainties related to tariffs and trade could disrupt supply chains and increase costs, impacting operational efficiency and profitability.
Canadian Revenue Decline: A 19% decline in Canadian revenue due to lower rig counts and general slowdown in activity levels could hinder overall revenue growth.
Stock-Based Compensation Costs: Increased expenses related to cash-settled stock awards, which are tied to the company's stock price, could pressure profitability.
Integration Risks: The integration of ResMetrix, while showing early successes, carries risks of potential delays or unforeseen challenges that could impact expected synergies and financial benefits.
Regulatory Hurdles: The need for independent third-party reviews for deepwater fracturing system solutions in the Gulf of America could delay project timelines and increase costs.
Fourth Quarter 2025 Revenue: Expected total revenue in the range of $41 million to $45 million. Canadian revenue is projected at $23 million to $25 million, U.S. revenue (including ResMetrix) at $15 million to $16 million, and international revenue at $3 million to $4 million.
Fourth Quarter 2025 Adjusted Gross Margin: Expected to range from 40% to 42%.
Fourth Quarter 2025 Adjusted EBITDA: Projected to range from $5 million to $6.5 million.
2025 Full-Year Revenue: Expected to range from $174 million to $178 million, representing year-over-year growth of 8%, with 5% organic growth and 3% contributed by ResMetrix.
2025 Full-Year Adjusted EBITDA: Narrowed to a range of $22.5 million to $24 million, with a midpoint of $23.25 million.
2025 Free Cash Flow: Expected to range from $11 million to $13 million after distributions to noncontrolling interest and excluding cash paid for ResMetrix, reflecting an increase of $3 million at the midpoint.
Market and Industry Conditions: Cautious outlook due to stagnating U.S. rig count, double-digit year-over-year activity declines in Canada, delays in unconventional jobs in Saudi Arabia, potential oversupply in the oil market from OPEC+ production, and uncertainties related to tariffs and trade.
Deepwater Fracturing System Deployment: Development customer plans to deploy the deepwater fracturing system solution in the Gulf of America, with drilling expected to commence in the second half of 2026.
Luminate Multi-Day Composite Sampling Units: To be showcased during the fourth quarter of 2025 to support a tracer diagnostics project, aimed at improving sample quality and reducing well site visits.
The selected topic was not discussed during the call.
The earnings call revealed strong financial performance, with significant revenue and EBITDA growth, particularly in the U.S. market. The successful integration of ResMetrix and promising opportunities in the Middle East and North Sea further enhance prospects. Despite some concerns about Canadian rig counts, the company plans to defend margins and grow market share. Shareholder returns are supported by a positive net cash position. The Q&A session provided additional confidence in strategic execution and market expansion, justifying a positive outlook for stock price movement.
The earnings call reflects strong financial performance with revenue exceeding expectations and improved EBITDA. Q2 revenue was the highest since 2019, and net income turned positive. Despite a slight decline in margins, cost management improved. The Q&A highlighted growth opportunities, particularly in Canada and international markets, and management's cautious optimism. Although there was some lack of clarity in guidance tightening, the overall sentiment is positive, supported by new customer wins and strategic focus on synergies and international expansion.
The company's earnings call reveals strong financial performance with a 14% YoY revenue increase, improved margins, and a positive net cash position. Despite geopolitical uncertainties and competitive pressures, the company maintains a favorable outlook with optimistic guidance and a solid cash position. The Q&A section highlights potential growth opportunities, particularly in international markets, and management's confidence in their technology portfolio. Although there are challenges in pricing and macroeconomic conditions, the overall sentiment remains positive, indicating a likely stock price increase in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.